domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -127,17 +127,23 @@ Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded an
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20*
+*Source: 2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics | Added: 2026-03-20*
 
 India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% price reduction (₹3,000-5,000/month vs ₹8,000-16,000 branded), with analysts projecting 90% price reduction over 5 years. Patents also expire in 2026 in Canada, Brazil, Turkey, China. University of Liverpool shows production costs as low as $3/month. US patents hold until 2031-2033, creating geographic bifurcation where international markets experience deflationary pressure starting 2026 while US remains inflationary through 2033.
 
 ---
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-21-natco-semaglutide-india-day1-launch-1290]] | Added: 2026-03-21*
+*Source: 2026-03-21-natco-semaglutide-india-day1-launch-1290 | Added: 2026-03-21*
 
 Natco Pharma launched generic semaglutide in India at ₹1,290/month ($15.50) on March 20, 2026, the day the patent expired. This is 90% below innovator pricing and 2-3x lower than analyst projections made days earlier ($40-77/month within a year). 50+ manufacturers from 40+ companies are entering the market, with Sun Pharma, Zydus, Dr. Reddy's, and Eris launching on Day 1. The 'inflationary through 2035' timeline is empirically wrong for international markets—price compression is happening in 2026, not 2030+.
 
+### Additional Evidence (challenge)
+*Source: [[2026-03-21-tirzepatide-patent-thicket-2041-glp1-bifurcation]] | Added: 2026-03-21*
+
+The claim treats GLP-1 agonists as a unified category with uniform chronic-use economics, but tirzepatide's patent thicket (2036 primary, 2041 formulation) creates 10-15 more years of exclusivity than semaglutide (2026-2033), bifurcating the market into a commodity tier (semaglutide generics, $15-77/month) and premium tier (tirzepatide, $1,000+/month) from 2026-2036. Any claim about 'GLP-1 economics' after 2026 must distinguish between these two drugs explicitly—they are now fundamentally different economic products with different cost trajectories.
+
+
 
 Relevant Notes:
 - [[the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline]] -- GLP-1s are the largest single contributor to the inflationary cost trajectory

domains/health/semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x.md

@@ -32,6 +32,12 @@ If a payer's goal is to maximize the probability of sustained adherence (and thu
 
 ---
 
+### Additional Evidence (extend)
+*Source: [[2026-03-21-tirzepatide-patent-thicket-2041-glp1-bifurcation]] | Added: 2026-03-21*
+
+The drug-specific adherence variation becomes economically critical with the tirzepatide/semaglutide bifurcation: if tirzepatide maintains higher persistence than semaglutide (as it did vs. liraglutide), the premium pricing may be justified by better real-world adherence. However, no head-to-head persistence data exists yet for tirzepatide vs. semaglutide at population scale. The bifurcation creates a natural experiment: will patients on generic semaglutide at $15-77/month show different persistence than those on branded tirzepatide at $1,000+/month? Affordability vs. efficacy becomes testable.
+
+
 Relevant Notes:
 - [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 - [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]

inbox/queue/.extraction-debug/2026-03-21-tirzepatide-patent-thicket-2041-glp1-bifurcation.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "tirzepatide-patent-thicket-extends-to-2041-creating-10-15-year-bifurcation-from-semaglutide-generics.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "cipla-dual-role-as-generic-semaglutide-entrant-and-lilly-tirzepatide-partner-exemplifies-portfolio-hedge-strategy.md",
+      "issues": [
+        "no_frontmatter"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "tirzepatide-patent-thicket-extends-to-2041-creating-10-15-year-bifurcation-from-semaglutide-generics.md:set_created:2026-03-21",
+      "cipla-dual-role-as-generic-semaglutide-entrant-and-lilly-tirzepatide-partner-exemplifies-portfolio-hedge-strategy.md:set_created:2026-03-21"
+    ],
+    "rejections": [
+      "tirzepatide-patent-thicket-extends-to-2041-creating-10-15-year-bifurcation-from-semaglutide-generics.md:missing_attribution_extractor",
+      "cipla-dual-role-as-generic-semaglutide-entrant-and-lilly-tirzepatide-partner-exemplifies-portfolio-hedge-strategy.md:no_frontmatter"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-21"
+}

inbox/queue/2026-03-21-tirzepatide-patent-thicket-2041-glp1-bifurcation.md

@@ -7,9 +7,13 @@ date: 2026-03-21
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp1, tirzepatide, mounjaro, zepbound, patent-thicket, eli-lilly, semaglutide-bifurcation, cipla-lilly, india-obesity]
+processed_by: vida
+processed_date: 2026-03-21
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -76,3 +80,14 @@ PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic catego
 WHY ARCHIVED: This source provides the structural basis for why the existing GLP-1 KB claim needs to be split into two claims — one for semaglutide (commodity trajectory) and one for tirzepatide (premium/inflationary trajectory). Without this distinction, any claim about "GLP-1 economics" after 2026 is ambiguous.
 
 EXTRACTION HINT: The extractor should focus on: (1) the specific patent thicket dates (2036 primary, 2041 last expiry); (2) the bifurcation structure — semaglutide vs. tirzepatide are now fundamentally different economic products; (3) Cipla's dual role as evidence of how the pharmaceutical industry is adapting to the bifurcation.
+
+
+## Key Facts
+- Tirzepatide primary compound patent expires January 5, 2036
+- Tirzepatide last patent (formulation/device thicket) expires approximately December 30, 2041
+- Tirzepatide patent challenge eligibility begins May 13, 2026
+- Semaglutide India patents expired March 20, 2026
+- Semaglutide US patents expire 2031-2033
+- Eli Lilly partnered with Cipla to launch tirzepatide under 'Yurpeak' brand in India
+- Lilly is filing for additional tirzepatide indications: heart failure, sleep apnea, kidney disease, MASH
+- i-mak.org documented GLP-1 patent evergreening strategies in 'Heavy Price of GLP-1 Drugs' report